David Hui1, Minjeong Park2, Omar Shamieh3, Carlos Eduardo Paiva4, Pedro Emilio Perez-Cruz5, Mary Ann Muckaden6, Eduardo Bruera1. 1. Department of Palliative Care and Rehabilitation Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Department of Palliative Care, King Hussein Cancer Center, Amman, Jordan. 4. Department of Medical Oncology, Barretos Cancer Hospital, Barretos, Brazil. 5. Department of Internal Medicine, School of Medicine, Pontifical Catholic University of Chile, Santiago, Chile. 6. Department of Palliative Care, Tata Memorial Center, Mumbai, India.
Abstract
BACKGROUND: Improving symptoms is a major goal of cancer medicine; however, symptom response is often based on group differences and not individualized. In the current study, the authors examined the personalized symptom goal (PSG) for 10 common symptoms in patients with advanced cancer, and identified the factors associated with PSG response. METHODS: In this prospective, longitudinal, multicenter study, patients from 5 tertiary care hospitals rated the intensity of 10 symptoms using a numeric rating scale of 0 to 10 at the time of their first clinic visit and then at a second visit 14 to 34 days later. The PSG was determined for each symptom by asking patients: "At what level would you feel comfortable with this symptom?" using the same scale of 0 to 10 for symptom intensity. PSG response was defined as symptom intensity at the time of the second visit that was less than or equal to the PSG. RESULTS: Among 728 patients, the median PSG was 1 for nausea; 2 for depression, anxiety, drowsiness, well-being, dyspnea, and sleep; and 3 for pain, fatigue, and appetite. A greater percentage of patients achieved a PSG response at their second visit compared with their first visit (P<.05 except for drowsiness). Symptom response was associated with lower baseline symptom intensity based on PSG criterion but higher baseline symptom intensity based on the traditional minimal clinically important difference definition (P<.001 for all symptoms). In multivariable analysis, higher PSG and nationality were associated with greater PSG response. CONCLUSIONS: The PSG was ≤3 for a majority of patients. PSG response allows clinicians to tailor treatment goals while adjusting for individual differences in scale interpretation and factors associated with symptom response. Cancer 2016;122:1774-81.
BACKGROUND: Improving symptoms is a major goal of cancer medicine; however, symptom response is often based on group differences and not individualized. In the current study, the authors examined the personalized symptom goal (PSG) for 10 common symptoms in patients with advanced cancer, and identified the factors associated with PSG response. METHODS: In this prospective, longitudinal, multicenter study, patients from 5 tertiary care hospitals rated the intensity of 10 symptoms using a numeric rating scale of 0 to 10 at the time of their first clinic visit and then at a second visit 14 to 34 days later. The PSG was determined for each symptom by asking patients: "At what level would you feel comfortable with this symptom?" using the same scale of 0 to 10 for symptom intensity. PSG response was defined as symptom intensity at the time of the second visit that was less than or equal to the PSG. RESULTS: Among 728 patients, the median PSG was 1 for nausea; 2 for depression, anxiety, drowsiness, well-being, dyspnea, and sleep; and 3 for pain, fatigue, and appetite. A greater percentage of patients achieved a PSG response at their second visit compared with their first visit (P<.05 except for drowsiness). Symptom response was associated with lower baseline symptom intensity based on PSG criterion but higher baseline symptom intensity based on the traditional minimal clinically important difference definition (P<.001 for all symptoms). In multivariable analysis, higher PSG and nationality were associated with greater PSG response. CONCLUSIONS: The PSG was ≤3 for a majority of patients. PSG response allows clinicians to tailor treatment goals while adjusting for individual differences in scale interpretation and factors associated with symptom response. Cancer 2016;122:1774-81.
Authors: Vanessa J Thomas; Catherine Seet-Lee; Michael Marthick; Birinder S Cheema; Michael Boyer; Kate M Edwards Journal: Support Care Cancer Date: 2019-05-21 Impact factor: 3.603
Authors: Joseph Arthur; Kimberson Tanco; Ali Haider; Courtney Maligi; Minjeong Park; Diane Liu; Eduardo Bruera Journal: Support Care Cancer Date: 2017-04-06 Impact factor: 3.603
Authors: Atul Batra; Lin Yang; Devon J Boyne; Andrew Harper; Winson Y Cheung; Colleen A Cuthbert Journal: Support Care Cancer Date: 2020-07-16 Impact factor: 3.603
Authors: Pedro E Perez-Cruz; Omar Shamieh; Carlos Eduardo Paiva; Jung Hye Kwon; Mary Ann Muckaden; Eduardo Bruera; David Hui Journal: J Pain Symptom Manage Date: 2017-11-16 Impact factor: 3.612